✦ LIBER ✦

Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)

✍ Scribed by Schmoll, H.-J.; Cunningham, D.; Sobrero, A.; Karapetis, C. S.; Rougier, P.; Koski, S. L.; Kocakova, I.; Bondarenko, I.; Bodoky, G.; Mainwaring, P.; Salazar, R.; Barker, P.; Mookerjee, B.; Robertson, J.; Van Cutsem, E.

Book ID: 119964457
Publisher: American Society of Clinical Oncology
Year: 2012
Tongue: English
Weight: 205 KB
Volume: 30
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2012.42.5355

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase III Trial of FOLFOX plus Bevacizum

Phase III Trial of FOLFOX plus Bevacizumab or Cediranib (AZD2171) as First-Line Treatment of Patients with Metastatic Colorectal Cancer: HORIZON III

✍ Jane D. Robertson; Nick A. Botwood; Mace L. Rothenberg; Hans-Joachim Schmoll 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 77 KB

Treatment Rationale and Study Design for

Treatment Rationale and Study Design for a Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination With Bevacizumab Plus mFOLFOX-6 in Patients With Previously Untreated Metastatic Colorectal Cancer

✍ Bendell, Johanna C.; Ervin, Thomas J.; Gallinson, David; Singh, Jaswinder; Walla 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 608 KB

Bevacizumab in Combination With Chemothe

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

✍ Ohtsu, A.; Shah, M. A.; Van Cutsem, E.; Rha, S. Y.; Sawaki, A.; Park, S. R.; Lim 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 203 KB

XELIRI-bevacizumab versus FOLFIRI-bevaci

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

✍ Dimitrios Pectasides, George Papaxoinis, Konstantine T Kalogeras, Anastasia G El 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 286 KB

The efficacy and safety of bevacizumab b

The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801)

✍ Goro Nakayama, Keisuke Uehara, Kiyoshi Ishigure… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 352 KB

Sunitinib Plus Paclitaxel Versus Bevaciz

Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial

✍ Nicholas J. Robert; Mansoor N. Saleh; Devchand Paul; Daniele Generali; Laurent G 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 798 KB